Literature DB >> 10588315

Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.

Y Onodera1, Y Uchida, M Tanaka, K Sato.   

Abstract

The in-vitro inhibitory activities of sitafloxacin (DU-6859a) and other quinolones against Streptococcus pneumoniae DNA gyrase and topoisomerase IV were measured. IC50s of levofloxacin, ciprofloxacin, sparfloxacin and tosufloxacin against DNA gyrase were almost three to 12 times higher than those against topoisomerase IV. On the other hand, sitafloxacin showed dual inhibitory activity against both enzymes and its IC50s were the lowest among those of the quinolones tested. These results suggest that sitafloxacin is an effective agent against pneumococcal infections and that the incidence of drug-resistant mutants is low.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10588315     DOI： 10.1093/jac/44.4.533

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  9 in total

1.  Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.

Authors:  M Takei; H Fukuda; R Kishii; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.

Authors:  Genoveva Yague; Julia E Morris; Xiao-Su Pan; Katherine A Gould; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.

Authors:  Julia E Morris; Xiao-Su Pan; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 5.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Sitafloxacin: in bacterial infections.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

7.  Quinolone Resistance: Older Concepts and Newer Developments.

Authors:  Darrin J. Bast; Joyce C. S. de Azavedo
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

8.  Sitafloxacin reduces tumor necrosis factor alpha (TNFα) converting enzyme (TACE) phosphorylation and activity to inhibit TNFα release from lipopolysaccharide-stimulated THP-1 cells.

Authors:  Ippei Sakamaki; Michika Fukushi; Wakana Ohashi; Yukie Tanaka; Kazuhiro Itoh; Kei Tomihara; Yoshihiro Yamamoto; Hiromichi Iwasaki
Journal:  Sci Rep       Date:  2021-12-17       Impact factor: 4.379

9.  Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis.

Authors:  Weerawat Manosuthi; Surasak Wiboonchutikul
Journal:  Springerplus       Date:  2016-04-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.